Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

By | April 30, 2021
Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).